IceCure Medical Announces Publication Of Independent Study In American Journal Of Roentgenology; Study Shows Recurrence-Free Rates Of 94.7%, 87.8%, And 81.8% At 1, 2, And 3 Years In Higher Risk Breast Cancer Patients Using Cryoablation
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical announced the publication of an independent study in the American Journal of Roentgenology, showing high recurrence-free rates in higher-risk breast cancer patients using cryoablation. The study reported rates of 94.7%, 87.8%, and 81.8% at 1, 2, and 3 years, respectively.
August 07, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IceCure Medical's cryoablation technology shows high recurrence-free rates in higher-risk breast cancer patients, as published in the American Journal of Roentgenology. This positive study could boost investor confidence and potentially increase the stock price.
The publication of a positive independent study in a reputable journal is likely to enhance the credibility of IceCure Medical's cryoablation technology. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100